$TEM earnings report

Tempus Reports Third Quarter 2026 Results. AlphAI read Tempus AI's Third Quarter 2026 filing as strong. 2 quarters are on record below.

Third Quarter 2026

AlphAI · Earnings readTEM · Third Quarter 2026 · ended September 30, 2026

Tempus Reports Third Quarter 2026 Results

✓Strong quarter

Third-quarter revenue increased 23%, Data and Applications grew 33%, gross profit increased 27%, and Adjusted EBITDA rose to $25.6 million from $1.5 million. The company increased full-year revenue guidance to $1.60 to $1.605 billion while maintaining expected full-year Adjusted EBITDA of ~$65 million.

Revenue
$412M
23 % y/y
Diagnostics, three months ended September 30, 2026
$303M
20% y/y
Gross margin · GAAP
64.8 %
EPS · non-GAAP
$ 0.07
164 % y/y
Full year 2026 outlook
$1.60 to $1.605 billion

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total net revenue, three months ended September 30, 2026GAAP$411.5M–23 %
Gross profit, three months ended September 30, 2026GAAP$266.7M–27 %
Gross margin, three months ended September 30, 2026GAAP64.8 %––
Non-GAAP gross profit, three months ended September 30, 2026non-GAAP$271.2M––
Non-GAAP gross margin, three months ended September 30, 2026non-GAAP65.9 %––
Technology research and development expense, three months ended September 30, 2026GAAP$45.71M––
Research and development expense, three months ended September 30, 2026GAAP$ 46,000––
Selling, general and administrative expense, three months ended September 30, 2026GAAP$231.9M––
Operating expenses, three months ended September 30, 2026GAAP$323.6M––
Non-GAAP operating expenses, three months ended September 30, 2026non-GAAP$256.8M––
Loss from operations, three months ended September 30, 2026GAAP−$56.86M–7 %
Non-GAAP income (loss) from operations, three months ended September 30, 2026non-GAAP$14.42M–267 %
Net loss, three months ended September 30, 2026GAAP−$14.85M–81 %
Net loss per share, basic and diluted, three months ended September 30, 2026GAAP$ (0.08 )–83 %
Non-GAAP net income (loss), three months ended September 30, 2026non-GAAP$13.36M–168 %
Non-GAAP net income (loss) per share, basic and diluted, three months ended September 30, 2026non-GAAP$ 0.07–164 %
Adjusted EBITDA, three months ended September 30, 2026non-GAAP$25.57M–1,633 %
Total net revenue, nine months ended September 30, 2026GAAP$1.14B––
Gross profit, nine months ended September 30, 2026GAAP$735.2M––
Gross margin, nine months ended September 30, 2026GAAP64.4 %––
Loss from operations, nine months ended September 30, 2026GAAP−$217.5M––
Non-GAAP income (loss) from operations, nine months ended September 30, 2026non-GAAP$134K––
Net loss, nine months ended September 30, 2026GAAP−$135.1M––
Net loss per share, basic and diluted, nine months ended September 30, 2026GAAP$ (0.75 )––
Non-GAAP net income (loss), nine months ended September 30, 2026non-GAAP−$16.98M––
Non-GAAP net income (loss) per share, basic and diluted, nine months ended September 30, 2026non-GAAP$ (0.09 )––
Adjusted EBITDA, nine months ended September 30, 2026non-GAAP$30.78M––
Net cash used in operating activities, nine months ended September 30, 2026GAAP−$71.59M––
Purchases of property and equipment, nine months ended September 30, 2026GAAP−$23.66M––
Net cash used in investing activities, nine months ended September 30, 2026GAAP−$38.68M––
Net cash provided by financing activities, nine months ended September 30, 2026GAAP$96.14M––

Segments

SegmentRevenueq/qy/y
Diagnostics, three months ended September 30, 2026Driven by Oncology volume growth of 32%, offset by Hereditary revenue growth of 3%.$303.5M–20%
Data and applications, three months ended September 30, 2026Insights grew 29%.$108.1M–33%
Diagnostics, nine months ended September 30, 2026No segment driver was provided for the nine-month period.$853.9M––
Data and applications, nine months ended September 30, 2026No segment driver was provided for the nine-month period.$288.2M––

Full year 2026 outlook

  • Revenue$1.60 to $1.605 billion
  • Note~25% annual growth
  • NoteAdjusted EBITDA of ~$65 million

What drove it

  • Oncology volume growth accelerated to 32%.
  • Minimal Residual Disease volume was ~12,000 tests, up 300%.
  • Data and Applications revenue increased 33%, with Insights increasing 29%.
  • Growth in Data and Applications led gross-profit growth.
  • In October, Tempus announced a BMS collaboration that brought total data licensing bookings to >$550 million year to date.
  • Tempus directly licensed oncology data and models to BMS for up to $137.5 million over a five-year term, while BMS and Pathos licensed Alzheimer’s or dementia data for $55 million over a five-year term.

Concerns

  • The company recorded a GAAP net loss of $ (14,851 ) in the third quarter and $ (135,128 ) for the nine months ended September 30, 2026.
  • GAAP operating expenses were $ 323,565 in the third quarter, including $ 231,857 of selling, general and administrative expense.
  • Third-quarter net loss included $50.8 million of stock-based compensation expense and related employer payroll taxes.
  • The company had convertible promissory note of 175,967 and convertible senior notes, net, of 1,174,877 at September 30, 2026.
  • The pending Personalis acquisition remained subject to shareholder approval, with the shareholder meeting planned for November 30, 2026.

What to watch

  • Execution against full-year 2026 revenue guidance of $1.60 to $1.605 billion and expected Adjusted EBITDA of ~$65 million.
  • Sustainability of 32% Oncology volume growth, ~12,000 MRD test volume, and 33% Data and Applications revenue growth.
  • Commercialization and data-licensing activity under the BMS, Merck, and Moderna collaborations.
  • The planned November 30, 2026 Personalis shareholder vote and the potential completion of the acquisition.
  • Progress toward building a research platform containing 100,000 whole genomes linked to longitudinal clinical information over the next several years.

Balance sheet and cash flow

  • Cash and cash equivalents at September 30, 2026: $ 590,479.
  • Marketable equity securities at September 30, 2026: $ 46,874 current and $ 212,276 less current portion.
  • Cash and marketable securities at quarter end: $854.4 million.
  • Convertible promissory note at September 30, 2026: 175,967.
  • Convertible senior notes, net, at September 30, 2026: 1,174,877.
  • Revolving credit facility at September 30, 2026: —.
  • Long-term debt, net, at September 30, 2026: —.
  • Net decrease in cash, cash equivalents and restricted cash for the nine months ended September 30, 2026: $ (14,217 ).
  • Proceeds from convertible senior notes, net of initial purchasers' discount, for the nine months ended September 30, 2026: 443,132.
  • Principal payments on long-term debt for the nine months ended September 30, 2026: (207,717 ).
  • Principal payments on revolving credit facility for the nine months ended September 30, 2026: (100,000 ).

Analysis

Tempus reported third-quarter GAAP revenue of $ 411,537, up 23 % from $ 334,206. Diagnostics generated $ 303,470, with 20% growth driven by Oncology volume growth of 32%, partly offset by Hereditary revenue growth of 3%. Data and applications generated $ 108,067 and grew 33%, while Insights grew 29%. MRD volume was ~12,000 tests, up 300%.

Gross profit rose 27 % to $ 266,701, and GAAP gross margin increased to 64.8 % from 62.8 %. Both major businesses expanded gross margin: Diagnostics gross margin was 62.4 % versus 61.0 %, and Data and applications gross margin was 71.5 % versus 68.5 %. The faster growth of Data and Applications and its higher reported gross margin were central to the gross-profit improvement.

GAAP loss from operations was $ (56,864 ), compared with $ (60,996 ). GAAP operating expenses were $ 323,565, including $ 231,857 of selling, general and administrative expense. On a non-GAAP basis, income from operations was $ 14,422 compared with a loss of $ (8,662 ), and Adjusted EBITDA was $ 25,572 compared with $ 1,476. The GAAP net loss narrowed to $ (14,851 ) from $ (79,982 ), while non-GAAP net income was $ 13,359. The third-quarter net loss included $50.8 million of stock-based compensation expense and related employer payroll taxes and $42.8 million in unrealized gains on marketable securities.

For the nine months ended September 30, 2026, total net revenue was $ 1,142,139 and Adjusted EBITDA was $ 30,783. Net cash used in operating activities improved to $ (71,586 ) from $ (181,302 ). At September 30, 2026, cash and cash equivalents were $ 590,479, while marketable equity securities were $ 46,874 current and $ 212,276 less current portion. The balance sheet also reported convertible promissory note of 175,967 and convertible senior notes, net, of 1,174,877.

Management increased full-year 2026 revenue guidance to $1.60 to $1.605 billion, representing ~25% annual growth, and continued to expect Adjusted EBITDA of ~$65 million. Commercial activity included the October BMS collaboration, which management said brought total data licensing bookings to >$550 million year to date, as well as a Merck and Moderna collaboration supporting potential commercialization of intismeran autogene. Regulatory review cleared for the pending Personalis acquisition, whose shareholder meeting is planned for November 30, 2026.

Management, verbatim

Q3 was another record quarter, as we delivered $411.5 million of revenue, led by accelerating unit growth of 32% in our oncology business and increasing momentum of 33% revenue growth in Data & Applications.

Eric Lefkofsky, founder and CEO of Tempus

Not in the filing

stated, not guessed
  • Prior-quarter comparisons were not reported for the presented operating metrics.
  • Free cash flow was not reported.
  • Quarterly operating cash flow was not reported.
  • Share repurchases were not reported.
  • Dividends were not reported.
  • Prior guidance was not provided, so comparison with prior guidance is unavailable.
  • Guidance for gross margin, operating expenses, and tax rate was not reported.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Second Quarter 2026

AlphAI · Earnings readTEM · Second Quarter 2026 · ended June 30, 2026

Tempus Reports Second Quarter 2026 Results

✓Strong quarter

Revenue increased 22% year-over-year to $382.5 million, gross profit increased 26% year-over-year to $246.5 million, and the company reported GAAP net income of $5.6 million and Adjusted EBITDA of $8.0 million. Tempus increased full-year 2026 revenue guidance to $1.595 to $1.605 billion.

Revenue
$382M
22 % y/y
Diagnostics
$289M
20% year-over-year growth y/y
EPS · non-GAAP
$ (0.04 )
(82 )% y/y
full year 2026 outlook
$1.595 to $1.605 billion

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
RevenueGAAP$382.5M–22 %
Gross profitGAAP$246.5M–26 %
Loss from operationsGAAP−$75.91M–23 %
Non-GAAP loss from operationsnon-GAAP−$2.71M–(84 )%
Net income (loss)GAAP$5.64M–113 %
Non-GAAP net lossnon-GAAP−$7.73M–(79 )%
Adjusted EBITDAnon-GAAP$8.04M–244 %
Net income (loss) per share, basicGAAP$ 0.03–112 %
Non-GAAP net loss per share, basicnon-GAAP$ (0.04 )–(82 )%
Oncology volume growthother31%–31% year-over-year
Molecular residual disease (MRD) volumeother9,000 tests––
Stock compensation expense and related employer payroll taxesGAAP$55.6M––
Unrealized gains on marketable securitiesGAAP$98.5M––

Segments

SegmentRevenueq/qy/y
DiagnosticsDriven by Oncology volume growth of 31%, offset by Hereditary revenue growth of 5%.$289.3M–20% year-over-year growth
Data and ApplicationsInsights growing 36%.$93.2M–28% year-over-year growth

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

full year 2026 outlook

  • Revenue$1.595 to $1.605 billion
  • Note~25% annual growth
  • NoteAdjusted EBITDA of ~$65 million
  • NoteGuidance assumes no impact from the Personalis transaction, which is expected to close in late Q4 2026 or early 2027.

What drove it

  • Diagnostics generated $289.3 million of revenue, driven by Oncology volume growth of 31%, offset by Hereditary revenue growth of 5%.
  • Data and Applications generated $93.2 million of revenue, with Insights growing 36%.
  • Gross profit increased 26% year-over-year to $246.5 million, led by growth in Data and Applications.
  • Signed large deals with BioNTech, Daiichi Sankyo, Level Set Bio, and Incyte Pharmaceuticals, contributing to ~$200 million in total bookings this quarter.
  • Received FDA approval for tumor-only xT CDx assay.
  • Successfully delivered the first version of its foundation model to AstraZeneca.

Concerns

  • GAAP loss from operations was $ (75,913 ).
  • Non-GAAP net loss was $ (7,726 ).
  • GAAP net income included $98.5 million in unrealized gains on marketable securities.
  • Guidance assumes no impact from the Personalis transaction.
  • The Personalis transaction is expected to close in late Q4 2026 or early 2027.

What to watch

  • Oncology volume growth of 31% year-over-year and molecular residual disease volume of 9,000 tests.
  • Data and Applications growth, including Insights growth of 36%.
  • Execution on ~$200 million in new Data and Applications licenses and total bookings this quarter.
  • Migration of tissue testing to ADLT pricing following FDA approval of xT Tumor Only.
  • Timing of the Personalis transaction, expected to close in late Q4 2026 or early 2027.
  • Delivery against full-year 2026 revenue guidance of $1.595 to $1.605 billion and expected Adjusted EBITDA of ~$65 million.

Balance sheet and cash flow

  • Cash and marketable securities of $820.7 million as of June 30, 2026.
  • Completed a $460 million offering of 0.0% convertible senior notes due 2032.

Analysis

Tempus reported second-quarter revenue of $382.5 million, up 22% year-over-year. Diagnostics generated $289.3 million, with 20% year-over-year growth, while Data and Applications generated $93.2 million, with 28% year-over-year growth. Within Diagnostics, Oncology volume growth was 31% year-over-year, compared with 28% last quarter, while Hereditary revenue growth was 5%. Within Data and Applications, Insights grew 36%.

Gross profit rose 26% year-over-year to $246.5 million, led by growth in Data and Applications. The company remained loss-making from operations, with a GAAP loss from operations of $ (75,913 ), although the non-GAAP loss from operations narrowed to $ (2,708 ) from $ (17,036 ). GAAP net income was $5.6 million, compared with a net loss of $(42.8 million) in Q2 of 2025, and included $98.5 million in unrealized gains on marketable securities and $55.6 million of stock compensation expense and related employer payroll taxes.

Adjusted EBITDA was $8.0 million, compared with ($5.6 million) in Q2 of 2025. Non-GAAP net loss was $ (7,726 ), and non-GAAP net loss per share, basic was $ (0.04 ). The quarter included 9,000 MRD tests, up from 6,500 last quarter. Tempus also cited large contracts with BioNTech, Daiichi Sankyo, Level Set Bio, and Incyte Pharmaceuticals contributing to ~$200 million in total bookings this quarter.

Capital resources included $820.7 million in cash and marketable securities as of June 30, 2026, and the company completed a $460 million offering of 0.0% convertible senior notes due 2032. Tempus raised its full-year 2026 revenue guidance to $1.595 to $1.605 billion, representing ~25% annual growth, while continuing to expect Adjusted EBITDA of ~$65 million. Guidance excludes any effect from the Personalis transaction, which is expected to close in late Q4 2026 or early 2027.

Strategically, the company announced an agreement to acquire Personalis for $16.25 per share (~$1.5 billion enterprise value), received FDA approval for tumor-only xT CDx assay, and delivered the first version of its foundation model to AstraZeneca. The reported period therefore combined accelerating Oncology volume growth, continued Data and Applications expansion, improved adjusted profitability, and a materially expanded strategic and financing agenda.

Management, verbatim

Q2 was another exceptional quarter for us,

Eric Lefkofsky, Founder and CEO of Tempus

Our strategy is working given the investments we have made in AI over the past several years are driving some of the best growth rates we have seen in our two largest businesses - Oncology Diagnostics and Data Licensing.

Eric Lefkofsky, Founder and CEO of Tempus

Through our existing collaboration with Personalis, we have already demonstrated the strength of combining highly sensitive MRD technology with our commercial infrastructure,

Eric Lefkofsky, Founder and CEO of Tempus

Not in the filing

stated, not guessed
  • GAAP gross margin
  • Non-GAAP gross profit
  • Non-GAAP gross margin
  • GAAP operating expenses
  • Non-GAAP operating expenses
  • Operating cash flow
  • Free cash flow
  • Capital expenditures
  • Debt balance
  • Share repurchases
  • Dividends
  • Diluted net income (loss) per share
  • Non-GAAP diluted net loss per share
  • Prior-quarter revenue
  • Prior-quarter gross profit
  • Prior-quarter GAAP loss from operations
  • Prior-quarter net income (loss)
  • Prior-quarter Adjusted EBITDA
  • Prior-quarter segment revenue
  • Prior guidance and comparison with actual results
  • Guidance for gross margin
  • Guidance for operating expenses
  • Guidance for tax rate

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about TEM earnings dates

When is Tempus AI's next earnings date?
AlphAI has no date for TEM yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.